Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Katja Weisel(Universität Hamburg), Paul G. Richardson(Harvard University), Alessandra Larocca(Cornell University), Marek Hus(Medical University of Lublin), Meletios Α. Dimopoulos(Korea University), Münci Yağcı(Gazi University), Ercan Muelduer, Tsvetan Biyukov(Bristol-Myers Squibb (Switzerland)), Lara Grote(Bristol-Myers Squibb (United States)), Paulo Lúcio(Champalimaud Foundation), Filiz Vural(Ege University), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Peter D. Byeff(University College Dublin), Abraham S. Kanate(West Virginia University), Maria‐Theresa Krauth(Medical University of Vienna), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Xin Yu(National Institutes of Health), Peter Johnson(Western General Hospital), Supratik Basu, Sujith Dhanasiri(Bristol-Myers Squibb (Switzerland)), Philippe Moreau(Centre National de la Recherche Scientifique), Patrick Hayden, Shien Guo(Ithaka Harbors), Pekka Anttila, Dina Ben‐Yehuda(Hebrew University of Jerusalem), Nicola Cascavilla
Cited by 13
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k